Employees: 02 (2023.0)Legal category: Société à responsabilité limitée (sans autre indication)Size: PMECreation date: 2009-08-13 (16 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: PERPIGNAN (66000), Pyrenees-Orientales
EURL L'APOTHEQUE DE LA GARE - PHARMACIE CALVET : revenue, balance sheet and financial ratios
EURL L'APOTHEQUE DE LA GARE - PHARMACIE CALVET is a French company
founded 16 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in PERPIGNAN (66000),
this company of category PME
shows in 2025 a revenue of 1.2 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - EURL L'APOTHEQUE DE LA GARE - PHARMACIE CALVET (SIREN 514261635)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
1 198 700 €
1 063 346 €
960 614 €
1 007 013 €
1 039 099 €
1 066 384 €
998 072 €
936 310 €
1 037 574 €
1 045 784 €
Net income
42 703 €
36 103 €
43 215 €
62 785 €
62 949 €
62 494 €
36 935 €
49 361 €
52 434 €
25 804 €
EBITDA
61 556 €
58 052 €
63 202 €
111 448 €
103 638 €
84 367 €
59 697 €
60 500 €
62 364 €
62 773 €
Net margin
3.6%
3.4%
4.5%
6.2%
6.1%
5.9%
3.7%
5.3%
5.1%
2.5%
Revenue and income statement
In 2025, EURL L'APOTHEQUE DE LA GARE - PHARMACIE CALVET achieves revenue of 1.2 M€. Revenue is growing positively over 10 years (CAGR: +1.5%). Vs 2024, growth of +13% (1.1 M€ -> 1.2 M€). After deducting consumption (887 k€), gross margin stands at 312 k€, i.e. a rate of 26%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 62 k€, representing 5.1% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 43 k€, i.e. 3.6% of revenue. This profit can be retained or distributed to shareholders.
Revenue (2025)
?
Revenue
Definition
Total amount of sales of goods and services made by the company.
Formula
Sales of goods + Sold production
1 198 700 €
Gross margin (2025)
?
Gross margin
Definition
Difference between revenue and cost of goods sold.
Formula
Revenue - Cost of goods consumed
311 751 €
EBITDA (2025)
?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity
61 556 €
EBIT (2025)
?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals
45 242 €
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
42 703 €
EBITDA margin (2025)
?
EBITDA margin
Definition
Measures the company's operating profitability.
Formula
(EBE / CA) x 100
Interpretation
> 10% : Good profitability 5-10% : Average < 5% : Low
5.1%
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 70%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 54%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 7.8 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high. Cash flow represents 4.9% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
69.626%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
53.512%
Cash flow / Revenue (2025)
?
Cash flow / Revenue
Definition
Self-financing capacity relative to revenue.
Formula
(CAF / CA) x 100
Interpretation
The higher the ratio, the more cash the company generates
4.94%
Repayment capacity (2025)
?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent 3-5 years : Fair > 5 years : Warning
7.794
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution EURL L'APOTHEQUE DE LA GARE - PHARMACIE CALVET
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
426.878
312.651
292.333
247.09
207.278
161.743
127.687
105.051
83.654
69.626
Financial autonomy
17.244
22.04
23.436
26.123
29.965
35.183
40.467
45.079
49.686
53.512
Repayment capacity
52.53
21.176
23.657
19.784
14.138
11.287
9.073
10.528
9.983
7.794
Cash flow / Revenue
1.684%
3.887%
4.255%
4.341%
5.766%
6.671%
7.633%
6.022%
4.892%
4.94%
Sector positioning
Debt ratio
69.632025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Average
In 2025, the debt ratio of EURL L'APOTHEQUE DE LA GA... (69.63) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
53.51%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Average
In 2025, the financial autonomy of EURL L'APOTHEQUE DE LA GA... (53.5%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Repayment capacity
7.79 years2025
2023
2024
2025
Q1: 0.51 years
Med: 2.46 years
Q3: 6.17 years
Average
In 2025, the repayment capacity of EURL L'APOTHEQUE DE LA GA... (7.79) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 81.85. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 7.9x. Operating income very largely covers interest expenses: high safety margin.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
81.846
Interest coverage (2025)
?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable 1.5-3 : Acceptable < 1.5 : Risk
7.868
Liquidity indicators evolution EURL L'APOTHEQUE DE LA GARE - PHARMACIE CALVET
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
130.573
124.828
132.477
78.96
144.712
135.167
133.679
108.609
81.579
81.846
Interest coverage
67.891
16.997
17.43
20.142
11.512
6.692
5.97
13.919
3.7
7.868
Sector positioning
Liquidity ratio
81.852025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Watch
In 2025, the liquidity ratio of EURL L'APOTHEQUE DE LA GA... (81.85) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
Interest coverage
7.87x2025
2023
2024
2025
Q1: 0.0x
Med: 1.91x
Q3: 5.98x
Excellent
In 2025, the interest coverage of EURL L'APOTHEQUE DE LA GA... (7.9x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 5 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 33 days. Favorable situation: supplier credit is longer than customer credit by 28 days. Inventory turnover is 21 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 22 days of revenue, i.e. 75 k€ to permanently finance. Notable WCR improvement over the period (-51%), freeing up cash.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
74 835 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
5 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
33 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
21 j
WCR in days of revenue (2025)
?
WCR in days of revenue
Definition
Expresses working capital requirement in days of revenue.
Formula
(Operating WCR / Revenue) x 360
Interpretation
The fewer days, the better the working capital management
22 j
WCR and payment terms evolution EURL L'APOTHEQUE DE LA GARE - PHARMACIE CALVET
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
151 806 €
112 691 €
136 673 €
100 516 €
90 419 €
91 752 €
107 015 €
102 766 €
69 479 €
74 835 €
Inventory turnover (days)
31
33
37
31
26
28
31
33
22
21
Customer payment term (days)
12
6
6
8
9
6
7
5
5
5
Supplier payment term (days)
40
35
42
43
29
32
36
38
40
33
Positioning of EURL L'APOTHEQUE DE LA GARE - PHARMACIE CALVET in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of EURL L'APOTHEQUE DE LA GARE - PHARMACIE CALVET is estimated at
591 506 €
(range 372 662€ - 810 506€).
With an EBITDA of 61 556€, the sector multiple of 7.7x is applied.
The price/revenue ratio is 0.61x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
372k€591k€810k€
591 506 €Range: 372 662€ - 810 506€
NAF 5 année 2025
Valuation detail by method
Ajustez les pondérations selon votre analyse
EBITDA Multiple50%
61 556 €×7.7x
Estimation475 231 €
239 657€ - 691 837€
Revenue Multiple30%
1 198 700 €×0.61x
Estimation727 409 €
535 895€ - 839 020€
Net Income Multiple20%
42 703 €×15.9x
Estimation678 342 €
460 326€ - 1 064 412€
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare EURL L'APOTHEQUE DE LA GARE - PHARMACIE CALVET with other companies in the same sector:
Frequently asked questions about EURL L'APOTHEQUE DE LA GARE - PHARMACIE CALVET
What is the revenue of EURL L'APOTHEQUE DE LA GARE - PHARMACIE CALVET ?
The revenue of EURL L'APOTHEQUE DE LA GARE - PHARMACIE CALVET in 2025 is 1.2 M€.
Is EURL L'APOTHEQUE DE LA GARE - PHARMACIE CALVET profitable?
Yes, EURL L'APOTHEQUE DE LA GARE - PHARMACIE CALVET generated a net profit of 43 k€ in 2025.
Where is the headquarters of EURL L'APOTHEQUE DE LA GARE - PHARMACIE CALVET ?
The headquarters of EURL L'APOTHEQUE DE LA GARE - PHARMACIE CALVET is located in PERPIGNAN (66000), in the department Pyrenees-Orientales.
Where to find the tax return of EURL L'APOTHEQUE DE LA GARE - PHARMACIE CALVET ?
The tax return of EURL L'APOTHEQUE DE LA GARE - PHARMACIE CALVET is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does EURL L'APOTHEQUE DE LA GARE - PHARMACIE CALVET operate?
EURL L'APOTHEQUE DE LA GARE - PHARMACIE CALVET operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart